ST
STAA.US STAAR Surgical Company
- Market cap
- USD 1.28B
- P/E
- 2,556.0x
- P/B
- 3.47x
- ROE
- 6.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is STAA.US undervalued?
Graham numberThe Graham number of STAAR Surgical Company cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
STAAR Surgical Company fundamental analysis
No fundamental analysis for STAAR Surgical Company yet.
STAAR Surgical Company stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health car…
Full company profileSTAAR Surgical Company financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
STAAR Surgical Company annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 82.4M | 90.6M | 124M | 150M | 163M | 230M | 284M | 322M | 314M | 239M | 361M |
| Gross Profit | 58.4M | 64.3M | 91.5M | 112M | 118M | 179M | 223M | 253M | 240M | 182M | 183M |
| Operating Income | -12.7M | -3.63M | 6.60M | 11.9M | 6.77M | 33.3M | 43.8M | 28.1M | -12.6M | -45.9M | 44.0M |
| EBITDA | -9.66M | -277K | 9.06M | 15.6M | 9.86M | 35.0M | 50.1M | 38.8M | -2.16M | -73.9M | 33.2M |
| Net Income | -12.1M | -2.14M | 4.97M | 14.0M | 5.91M | 27.5M | 39.7M | 21.3M | -20.2M | -80.4M | 25.1M |
| EPS | -0.30 | -0.05 | 0.11 | 0.30 | 0.12 | 0.56 | 0.80 | 0.43 | -0.41 | -1.62 | 0.49 |
| Balance Sheet | |||||||||||
| Total Assets | 65.4M | 67.9M | 167M | 208M | 257M | 346M | 419M | 489M | 510M | 452M | 485M |
| Total Liabilities | 27.5M | 25.0M | 34.9M | 47.6M | 60.2M | 87.2M | 82.7M | 103M | 112M | 107M | 109M |
| Shareholders' Equity | 37.9M | 42.9M | 132M | 160M | 197M | 259M | 336M | 386M | 397M | 344M | 376M |
| Cash & Short-term Investments | 14.0M | 18.5M | 104M | 120M | 152M | 200M | 212M | 221M | 230M | 188M | 206M |
| Total Debt | 6.82M | 6.25M | 5.34M | 9.54M | 10.8M | 32.1M | 31.0M | 35.8M | 38.7M | 38.4M | 33.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.05M | 2.85M | 12.8M | 25.8M | 21.0M | 44.0M | 35.7M | 14.6M | 15.7M | -34.2M | 33.7M |
| Capital Expenditure | 3.21M | 1.05M | 2.25M | 10.2M | 8.40M | 13.6M | 18.1M | 18.2M | 23.4M | 5.82M | 2.50M |
| Free Cash Flow | -2.16M | 1.81M | 10.5M | 15.6M | 12.5M | 30.3M | 17.6M | -3.59M | -7.67M | -40.1M | -3.89M |
| Ratios | |||||||||||
| ROE | -32.0% | -5.0% | 3.8% | 8.8% | 3.0% | 10.6% | 11.8% | 5.5% | -5.1% | -23.4% | 6.7% |
| ROA | -18.5% | -3.1% | 3.0% | 6.8% | 2.3% | 8.0% | 9.5% | 4.4% | -4.0% | -17.8% | 5.2% |
| Net Profit Margin | -14.7% | -2.4% | 4.0% | 9.4% | 3.6% | 11.9% | 13.9% | 6.6% | -6.4% | -33.6% | 7.0% |
| Debt to Equity | 0.18x | 0.15x | 0.04x | 0.06x | 0.05x | 0.12x | 0.09x | 0.09x | 0.10x | 0.11x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
STAAR Surgical Company dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 9.67K | 0.00 | 0.0% |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 5.20M | 0.11 | 104.6% |
| 2017 | USD 3.97M | 0.10 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:2 on May 18, 1992.
Who owns STAAR Surgical Company
- Insiders 0.85%
- Institutions 99.15%
- Public & others 0.00%
- Shares outstanding 50.2M
- Free float 26.2M
Top funds holding STAA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 1.82M | 3.62% | +0.06% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 949K | 1.89% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 769K | 1.53% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 678K | 1.35% | -1.31% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 377K | 0.75% | -3.88% | Sep 2026 |
| Fidelity Small Cap Index | 374K | 0.74% | +0.74% | Aug 2026 |
| Vanguard Tax-Managed Small Cap Adm | 312K | 0.62% | 0.00% | Sep 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 274K | 0.55% | -0.05% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 258K | 0.51% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 178K | 0.35% | -8.81% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 162K | 0.32% | +0.24% | Oct 2026 |
| DFA US Micro Cap I | 158K | 0.32% | +6.04% | Sep 2026 |
| GuideStone Funds Small Cap Equity Instl | 143K | 0.28% | -5.91% | Oct 2026 |
| Fidelity Extended Market Index | 143K | 0.28% | -41.90% | Sep 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 142K | 0.28% | 0.00% | Oct 2026 |
| DFA U.S. Small Cap I | 137K | 0.27% | +2.42% | Sep 2026 |
| Dimensional US Small Cap ETF | 122K | 0.24% | 0.00% | Oct 2026 |
| iShares S&P Small-Cap 600 Value ETF | 119K | 0.24% | 0.00% | Oct 2026 |
| Dimensional US Core Equity 2 ETF | 108K | 0.22% | +0.86% | Oct 2026 |
| Vanguard S&P Small-Cap 600 ETF | 107K | 0.21% | -40.29% | Sep 2026 |
Top institutions holding STAA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BROADWOOD CAPITAL Inc | 16.1M | 32.12% | 0.00% | Jun 2026 |
| BlackRock Inc | 6.73M | 13.41% | +0.98% | Jun 2026 |
| Madison Avenue Partners, LP | 4.18M | 8.32% | +71.02% | Jun 2026 |
| Yunqi Capital Ltd | 3.26M | 6.49% | 0.00% | Jun 2026 |
| Point72 Asset Management, L.P. | 2.44M | 4.86% | +196.11% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.15M | 4.28% | +101.02% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.98M | 3.94% | -6.78% | Jun 2026 |
| State Street Corp | 1.77M | 3.52% | -3.47% | Jun 2026 |
| Anatole Investment Management Ltd | 1.65M | 3.29% | +3.12% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.55M | 3.09% | -8.15% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.32M | 2.62% | -12.22% | Jun 2026 |
| Geode Capital Management, LLC | 1.08M | 2.14% | +5.85% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 860K | 1.71% | -0.79% | Sep 2026 |
| American Capital Management Inc | 847K | 1.69% | -3.57% | Jun 2026 |
| AI-Squared Management Ltd | 542K | 1.08% | +102.33% | Jun 2026 |
| Renaissance Technologies Corp | 492K | 0.98% | +44.51% | Sep 2026 |
| Charles Schwab Investment Management Inc | 446K | 0.89% | +9.09% | Jun 2026 |
| Defender Capital, LLC. | 430K | 0.86% | -0.33% | Sep 2026 |
| Northern Trust Corp | 423K | 0.84% | +5.72% | Jun 2026 |
| NORGES BANK | 365K | 0.73% | 0.00% | Jun 2026 |
STAAR Surgical Company company profile
- Company name
- STAAR Surgical Company
- Ticker
- STAA.US
- Exchange
- USA Stocks
- Listed since
- Jul 15, 1983
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 921
- Fiscal year end
- December
- Address
- 25510 Commercentre Drive, Lake Forest, CA, United States, 92630
- Phone
- 626 303 7902
- Website
- staar.com
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
STAAR Surgical Company management
10- Mr. Warren FoustCEO, President & Director · born 1976
- Ms. Deborah J. AndrewsExecutive VP & CFO · born 1957
- Dr. Magda Michna Ph.D.Chief Development Officer
- Dr. Ben Park Ph.D.Chief Technology Officer
- Ms. Connie JohnsonDirector of Investor Relations
- Ms. Kathleen Determann J.D.VP, Deputy General Counsel and Chief Compliance & Privacy Officer
- Mr. William W. GoodmenVice President of Global Human Resources · born 1955
- Mr. David BaileyChief Commercial Officer · born 1957
- Dr. Scott D. Barnes M.D.Chief Medical Officer · born 1963
- Mr. Filip De KeersmaeckerChief Supply Chain & Quality Officer